Methods and role of minimal residual disease after stem cell transplantation

Marco Ladetto; Sebastian Böttcher; Nicolaus Kröger; Michael A Pulsipher; Peter Bader

doi:10.1038/s41409-018-0307-1

Methods and role of minimal residual disease after stem cell transplantation

Standard

Methods and role of minimal residual disease after stem cell transplantation. / Ladetto, Marco; Böttcher, Sebastian; Kröger, Nicolaus; Pulsipher, Michael A; Bader, Peter.

in: BONE MARROW TRANSPL, Jahrgang 54, Nr. 5, 05.2019, S. 681-690.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ladetto, M, Böttcher, S, Kröger, N, Pulsipher, MA & Bader, P 2019, 'Methods and role of minimal residual disease after stem cell transplantation', BONE MARROW TRANSPL, Jg. 54, Nr. 5, S. 681-690. https://doi.org/10.1038/s41409-018-0307-1

APA

Ladetto, M., Böttcher, S., Kröger, N., Pulsipher, M. A., & Bader, P. (2019). Methods and role of minimal residual disease after stem cell transplantation. BONE MARROW TRANSPL, 54(5), 681-690. https://doi.org/10.1038/s41409-018-0307-1

Vancouver

Ladetto M, Böttcher S, Kröger N, Pulsipher MA, Bader P. Methods and role of minimal residual disease after stem cell transplantation. BONE MARROW TRANSPL. 2019 Mai;54(5):681-690. https://doi.org/10.1038/s41409-018-0307-1

Bibtex

@article{524d696b3a14490b9107a808ea30ad2f,

title = "Methods and role of minimal residual disease after stem cell transplantation",

abstract = "Relapse is the major cause of treatment failure after stem cell transplantation. Despite the fact that relapses occurred even if transplantation was performed in complete remission, it is obvious that minimal residual disease is present though not morphologically evident. Since adaptive immunotherapy by donor lymphocyte infusion or other novel cell therapies as well as less toxic drugs, which can be used after transplantation, the detection of minimal residual disease (MRD) has become a clinical important variable for outcome. Besides the increasing options to treat MRD, the most advanced technologies currently allow to detect residual malignant cells with a sensitivity of 10-5 to 10-6.Under the patronage of the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) the 3rd workshop was held on 4/5 November 2016 in Hamburg/Germany, with the aim to present an up-to-date status of epidemiology and biology of relapse and to summarize the currently available options to prevent and treat post-transplant relapse. Here the current methods and role of minimal residual disease for myeloid and lymphoid malignancies are summarized.",

keywords = "Journal Article",

author = "Marco Ladetto and Sebastian B{\"o}ttcher and Nicolaus Kr{\"o}ger and Pulsipher, {Michael A} and Peter Bader",

year = "2019",

month = may,

doi = "10.1038/s41409-018-0307-1",

language = "English",

volume = "54",

pages = "681--690",

journal = "BONE MARROW TRANSPL",

issn = "0268-3369",

publisher = "NATURE PUBLISHING GROUP",

number = "5",

}

RIS

TY - JOUR

T1 - Methods and role of minimal residual disease after stem cell transplantation

AU - Ladetto, Marco

AU - Böttcher, Sebastian

AU - Kröger, Nicolaus

AU - Pulsipher, Michael A

AU - Bader, Peter

PY - 2019/5

Y1 - 2019/5

N2 - Relapse is the major cause of treatment failure after stem cell transplantation. Despite the fact that relapses occurred even if transplantation was performed in complete remission, it is obvious that minimal residual disease is present though not morphologically evident. Since adaptive immunotherapy by donor lymphocyte infusion or other novel cell therapies as well as less toxic drugs, which can be used after transplantation, the detection of minimal residual disease (MRD) has become a clinical important variable for outcome. Besides the increasing options to treat MRD, the most advanced technologies currently allow to detect residual malignant cells with a sensitivity of 10-5 to 10-6.Under the patronage of the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) the 3rd workshop was held on 4/5 November 2016 in Hamburg/Germany, with the aim to present an up-to-date status of epidemiology and biology of relapse and to summarize the currently available options to prevent and treat post-transplant relapse. Here the current methods and role of minimal residual disease for myeloid and lymphoid malignancies are summarized.

AB - Relapse is the major cause of treatment failure after stem cell transplantation. Despite the fact that relapses occurred even if transplantation was performed in complete remission, it is obvious that minimal residual disease is present though not morphologically evident. Since adaptive immunotherapy by donor lymphocyte infusion or other novel cell therapies as well as less toxic drugs, which can be used after transplantation, the detection of minimal residual disease (MRD) has become a clinical important variable for outcome. Besides the increasing options to treat MRD, the most advanced technologies currently allow to detect residual malignant cells with a sensitivity of 10-5 to 10-6.Under the patronage of the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) the 3rd workshop was held on 4/5 November 2016 in Hamburg/Germany, with the aim to present an up-to-date status of epidemiology and biology of relapse and to summarize the currently available options to prevent and treat post-transplant relapse. Here the current methods and role of minimal residual disease for myeloid and lymphoid malignancies are summarized.

KW - Journal Article

U2 - 10.1038/s41409-018-0307-1

DO - 10.1038/s41409-018-0307-1

M3 - SCORING: Journal article

C2 - 30116018

VL - 54

SP - 681

EP - 690

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 5

ER -